CDK4 and breast cancer: The CDK 4/6 inhibitor (CDK4/6i) palbociclib, which arrests cells in G1 phase, has been approved by the FDA for the treatment of ER-positive advanced BC [16–19] and is expected to provide new treatment strategies for TNBC patients, especially the luminal androgen receptor (LAR) subtype of TNBC [20].